Get the Stockscreener App
127.27
0.41%
-0.53
Pre-market:
127.60
0.33
+0.26%
Insmed Inc stock is traded at $127.27, with a volume of 3.43M.
It is down -0.41% in the last 24 hours and up +24.10% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$127.80
Open:
$127.8
24h Volume:
3.43M
Relative Volume:
0.91
Market Cap:
$26.90B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-22.37
EPS:
-5.69
Net Cash Flow:
$-868.57M
1W Performance:
+12.74%
1M Performance:
+24.10%
6M Performance:
+56.43%
1Y Performance:
+67.02%
1-Day Range:
$127.12
$130.13
1-Week Range:
$112.48
$130.13
52-Week Range:
$60.40
$130.13
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
127.27 | 27.01B | 398.11M | -1.03B | -868.57M | -5.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.88 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.87 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.91 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
661.32 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.32 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Will Insmed Incorporated outperform the marketEarnings Growth Summary & Free Verified High Yield Trade Plans - Newser
Insmed Announces FDA Approval For Drug To Treat Chronic Lung Disease - MSN
What to do if you’re stuck in Insmed Incorporated2025 Stock Rankings & Weekly High Return Stock Opportunities - Newser
Is This a Bottoming Phase for Insmed Incorporated2025 Analyst Calls & Smart Money Movement Tracker - kangso.co.kr
Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market - Yahoo Finance
Non-Cystic Fibrosis Bronchiectasis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring - Barchart.com
Insmed announces FDA approval of Brinsupri for NCFB - MSN
Is Insmed Incorporated stock entering bullish territoryTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
Insmed's Brinsupri: A Game-Changer in the $3.7B Bronchiectasis Market and a Catalyst for Shareholder Value - AInvest
Insmed's Arikayce Approval and Implications of Brinsupri Approval - AInvest
Insmed: What The Approval Of Brinsupri Will Change? - Seeking Alpha
Is Insmed Incorporated stock forming a cup and handleWeekly Volume Report & Weekly Setup with High ROI Potential - thegnnews.com
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $173 - 富途牛牛
Insmed Director Makes a Major Move with Stock Sale! - TipRanks
Insmed's Stock Jumps 3.97% on FDA Approval, Hits $590M Top 500 Daily Volume - AInvest
Insmed Stock Surges 8.07% As Bullish Candlestick Pattern Signals Uptrend Continuation - AInvest
Insmed Stock Closes At Nearly 25-Year High As Analysts Get Bullish On FDA Nod For Lung Disease Drug: Retail Traders Ecstatic - MSN
Stifel Raises Price Target for Insmed to $145 - AInvest
Insmed Stock Soars: What’s Next? - StocksToTrade
Truist Securities maintains Buy rating on Insmed with PT raised to $139. - AInvest
Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Truist Securities raises Insmed stock price target to $139 on brensocatib pricing - Investing.com Canada
Insmed price target raised to $145 from $121 at Stifel - TipRanks
Insmed price target raised to $139 from $126 at Truist - TipRanks
Insmed downgraded to Equal Weight from Overweight at Morgan Stanley - MSN
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $139 to $240 - 富途牛牛
Insmed stock price target raised to $240 from $120 at H.C. Wainwright - Investing.com Canada
Published on: 2025-08-14 16:09:54 - beatles.ru
Insmed stock price target raised to $173 from $109 at Wolfe Research - Investing.com Canada
Insmed Incorporated shares rise 3.37% premarket after multiple price target adjustments from UBS, RBC Capital, Mizuho, and Morgan Stanley. - AInvest
Insmed Incorporated May Be Forming Higher Low — Chartwatchers AlertJuly 2025 Breakouts & Real-Time Buy Signal Notifications - 선데이타임즈
Insmed Rises 0.71% as Volume Ranks 224th Post-FDA Approval Price Target Hiked to 240 - AInvest
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval - MSN
Insmed: HC Wainwright Raises PT to $240 from $120, Maintains Buy Rating - AInvest
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week - MSN
Insmed and VytlOne: A Groundbreaking Partnership in Rare Disease Innovation - AInvest
VytlOne Announces New Partnership with Insmed - Eastern Progress
Insmed stock downgraded at Morgan Stanley (INSM:NASDAQ) - Seeking Alpha
Insmed stock price target raised to $154 from $135 at TD Cowen on Brinsupri approval - Investing.com Canada
Goldman Sachs Raises Insmed Buy Rating to $142, PT from $114 - AInvest
Insmed stock price target raised to $138 from $120 at RBC Capital - Investing.com Canada
UBS Adjusts Insmed Price Target to $140 From $133, Maintains Buy Rating - MarketScreener
PANTHERx® Rare Selected by Insmed to Dispense BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis - Yahoo Finance
Insmed wins FDA approval for future blockbuster Brinsupri - Yahoo Finance
Mizuho raises Insmed stock price target to $165 following Brinsupri approval - Investing.com Canada
Morgan Stanley Downgrades Insmed to Equal Weight From Overweight, Adjusts Price Target to $126 From $112 - MarketScreener
Mizuho Adjusts Price Target on Insmed to $165 From $130, Maintains Outperform Rating - MarketScreener
Mizuho Raises Price Target for Insmed (INSM) to $165 | INSM Stoc - GuruFocus
Insmed secures FDA approval for Brinsupri to treat NCFB - World Pharmaceutical Frontiers
Insmed stock price target raised to $140 from $130 at Wells Fargo - Investing.com Canada
Jefferies Raises Price Target on Insmed (INSM) to $148 | INSM Stock News - GuruFocus
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):